Inhibition of nitric oxide synthase during sepsis: revival because of isoform selectivity?
Stahl
Wolfgang
W
Matejovic
Martin
M
Radermacher
Peter
P
D000138:Acidosis / Q000517:prevention & control; D000818:Animals; D001775:Blood Circulation / Q000187:drug effects; D017322:Clinical Trials, Phase II as Topic; D057239:Early Termination of Clinical Trials; D019446:Endotoxemia / Q000201:enzymology; D005440:Fluid Therapy; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D018345:Mice, Knockout; D008981:Molsidomine / Q000031:analogs & derivatives / Q000627:therapeutic use; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D018805:Sepsis / Q000201:enzymology*; D012772:Shock, Septic / Q000201:enzymology; D013552:Swine; D019323:omega-N-Methylarginine / Q000494:pharmacology / Q000627:therapeutic use
C507627:2-(2-(4-methoxypyridin-2-yl)ethyl)-3H-imidazo(4,5-b)pyridine; D007093:Imidazoles; D020033:Protein Isoforms; D011725:Pyridines; D019323:omega-N-Methylarginine; C002385:linsidomine; D008981:Molsidomine; D052247:Nitric Oxide Synthase Type II; D009638:Norepinephrine